echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Science Sub-Journal: An Orthogonal IL-2/IL-2Rβ System Promotes Persistence of CAR-T Cells and Enhances Tumor Clearance

    Science Sub-Journal: An Orthogonal IL-2/IL-2Rβ System Promotes Persistence of CAR-T Cells and Enhances Tumor Clearance

    • Last Update: 2022-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chimeric antigen receptor (CAR) T cells (CAR-T) induce durable responses in patients with refractory hematological malignancies


    Interleukin-2 (IL-2) is an important cytokine that activates T cells and is considered a way to treat cancer


    In a new study, researchers from Synthekine in the United States report an orthogonal IL-2 receptor/ligand system that can specifically control the proliferation and activation of CAR-T cells in vivo.


    CAR-T cell manufacturing pipeline, image from Gene Therapy, 2021, doi:10.


    T cells were genetically engineered to express the receptor hoRb, which can only be activated by STK-009


    In a preclinical model of human CAR-refractory lymphoma, STK-009 treatment resulted in systemic and intratumoral proliferation and activation of hoRb-expressing anti-CD19-CD28ζ CAR-T cells (SYNCAR)


    References:

    Paul-Joseph Aspuria et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.